MedTrace Logo

Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function

NCT00541814 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2008-09-08

No results posted yet for this study

Summary

The purpose of this trial is to ascertain whether the withdrawal of calcineurin inhibitors (CNI) will lead to less kidney transplant damage when compared with minimisation. The investigators will assess this by comparing the degree of damage on kidney biopsies taken before and after minimisation/withdrawal of CNI.

Conditions

  • Chronic Allograft Nephropathy

Interventions

DRUG

Cyclosporine

Target drug level 50-100 ng/ml or cyclosporine withdrawal

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University Hospital Birmingham

    lead OTHER

Principal Investigators

  • Richard Borrows, MRCP · University Hospital Birmingham NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Completion
2010-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00541814 on ClinicalTrials.gov